- Phase 2b study completed in amyotrophic lateral sclerosis (ALS) demonstrated lead asset PrimeC slows disease progression and functional decline
- Ongoing partnership discussions to advance PrimeC to Phase 3 study in ALS and commercialization
- Phase 3 study design for PrimeC in ALS aligned with FDA; planned initiation in 2025
CAMBRIDGE, Mass., April 7, 2025 -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a clinical-stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today reports its financial results for the year ended December 31, 2024 and provides a business update.
Business highlights from 2024 and to date
- PrimeC achieved primary and secondary clinical endpoints in PARADIGM Phase 2b study investigating PrimeC in ALS (n=68) with data showing the following:
- PrimeC slowed disease progression (measured by ALSFRS-R) by approximately 33% after 18 months (p=0.007)
- PrimeC reduced likelihood of mortality, hospitalization and respiratory support, resulting in an overall 58% improvement in survival rates.
- PrimeC slowed functional decline, especially speaking and swallowing functions.
- PrimeC demonstrated favorable safety and tolerability profile, achieving the study's primary endpoint. - Phase 3 study design for PrimeC for ALS aligned with FDA following Type C meeting.
- Partnership discussions are continuing in order to advance PrimeC towards regulatory approval and eventual commercialization.
- Plans to file for early commercialization for PrimeC in Canada, with an estimated potential market opportunity of $100m-$150m in peak annual revenues.
- Key patent granted by U.S. Patent and Trademark Office (USPTO), extending the patent protection for the novel formulation of PrimeC until 2042.
"2024 was a year of significant clinical progress for NeuroSense," stated NeuroSense CEO, Alon Ben-Noon. "We successfully completed our Phase 2b study for PrimeC in ALS, with data showing transformative results in a neurodegenerative indication of immense medical need. The results conclude with PrimeC's disease-modifying potential and strongly support advancing PrimeC towards a Phase 3 study. With positive FDA feedback on the proposed study design, we are putting everything in place for the next stage of NeuroSense's growth, driven by PrimeC's continued clinical development."
Financial Results
Research and development expenses for the years ended December 31, 2024 and 2023 were $5.7 million and $7.3 million, respectively. The decrease of $1.6, or 21.9%, was mainly attributed to a decrease in our expenses to subcontractors and consultants and a decrease in share-based payment expense.
General and administrative expenses for the years ended December 31, 2024 and 2023 were $4.2 million and $4.8 million, respectively. The decrease of $0.6, or 12.5%, was mainly attributed to a decrease in share-based compensation and insurance costs and a decrease in salaries and social benefit expenses mainly due to decrease in the number of employees which were offset by an increase in professional services expenses.
As of December 31, 2024, NeuroSense had cash of approximately $3.4 million.
A summary of NeuroSense's consolidated financial results is included in the tables below.
A copy of the Company's annual report on Form 20-F for the year ended December 31, 2024 has been filed with the U.S. Securities and Exchange Commission at https://www.sec.gov/ and posted on the Company's investor relations website at https://neurosense.investorroom.com/sec-filings. The Company will deliver a hard copy of its annual report, including its complete audited financial statements, free of charge, to its shareholders upon request at ir@neurosense-tx.com.
NeuroSense Therapeutics Ltd. | ||||||||||
Consolidated Statements of Financial Position | ||||||||||
(U.S. dollars in thousands, except share and per share data) | ||||||||||
As of December 31, | ||||||||||
2024 | 2023 | |||||||||
Assets | ||||||||||
Current assets: | ||||||||||
Cash and cash equivalent | $ | 3,378 | $ | 2,640 | ||||||
Other receivables | 989 | 236 | ||||||||
Restricted deposits | 35 | 40 | ||||||||
Total current assets | 4,402 | 2,916 | ||||||||
Non-current assets: | ||||||||||
Property and equipment, net | 66 | 85 | ||||||||
Right of use assets | 84 | 162 | ||||||||
Restricted deposit | 23 | 22 | ||||||||
Total non-current assets | 173 | 269 | ||||||||
Total assets | $ | 4,575 | $ | 3,185 | ||||||
Liabilities shareholders' and equity | ||||||||||
Current liabilities: | ||||||||||
Trade payables | $ | 1,160 | $ | 1,459 | ||||||
Other current liabilities | 832 | 2,000 | ||||||||
Total current liabilities | 1,992 | 3,459 | ||||||||
Non-current liabilities: | ||||||||||
Lease liability less current maturity | - | 73 | ||||||||
Liability in respect of warrants | - | 1,412 | ||||||||
- | 1,485 | |||||||||
Total liabilities | 1,992 | 4,944 | ||||||||
Shareholders' equity: | ||||||||||
Ordinary shares, no par value: | ||||||||||
Authorized: 90,000,000 shares at December 31, 2024 and 60,000,000 | - | |||||||||
Share Premium and Capital Reserve | 39,243 | 24,362 | ||||||||
Accumulated deficit | (36,660) | (26,121) | ||||||||
Total shareholders' equity (deficit) | 2,583 | (1,759) | ||||||||
Total liabilities and shareholders' equity | $ | 4,575 | $ | 3,185 | ||||||
NeuroSense Therapeutics Ltd. | ||||||||||||||
Consolidated Statements of Income and Comprehensive Loss | ||||||||||||||
(U.S. dollars in thousands, except share and per share data) | ||||||||||||||
For the year ended | ||||||||||||||
2024 | 2023 | 2022 | ||||||||||||
Research and development expenses | $ | (5,698) | $ | (7,274) | $ | (5,587) | ||||||||
General and administrative expenses | (4,204) | (4,775) | (4,967) | |||||||||||
Operating loss | (9,902) | (12,049) | (10,554) | |||||||||||
Financing income (expenses), net | (308) | 1,942 | 62 | |||||||||||
Net loss and comprehensive loss | $ | (10,210) | $ | (10,107) | $ | (10,492) | ||||||||
Basic and diluted net loss per share | $ | (0.54) | $ | (0.74) | $ | (0.91) | ||||||||
NeuroSense Therapeutics Ltd. | ||||||||||||||||||||
Consolidated Statements of Changes in Equity (deficit) | ||||||||||||||||||||
(U.S. dollars in thousands, except share and per share data) | ||||||||||||||||||||
Ordinary | Share | Accumulated | Total | |||||||||||||||||
Number | Amount | Reserve | Deficit | (Deficit) | ||||||||||||||||
Balance as of January 1, 2022 | 10,943,534 | $ | - | $ | 16,356 | $ | (5,522) | $ | 10,834 | |||||||||||
Repurchase of options | - | - | (96) | - | (96) | |||||||||||||||
Exercise of warrants and vested RSUs | 838,429 | - | 3,870 | - | 3,870 | |||||||||||||||
Share based payment compensation | - | - | 1,728 | - | 1,728 | |||||||||||||||
Net loss and comprehensive loss | - | - | - | (10,492) | (10,492) | |||||||||||||||
Balance as of December 31, 2022 | 11,781,963 | $ | - | $ | 21,858 | $ | (16,014) | $ | 5,844 | |||||||||||
Issuance of shares and pre-funded warrants, net | 1,333,600 | - | 806 | - | 806 | |||||||||||||||
Exercise of pre-funded warrants, options and | 2,263,479 | - | - | - | - | |||||||||||||||
Share based payment compensation | - | - | 1,698 | - | 1,698 | |||||||||||||||
Net loss and comprehensive loss | - | - | - | (10,107) | (10,107) | |||||||||||||||
Balance as of December 31, 2023 | 15,379,042 | $ | - | $ | 24,362 | $ | (26,121) | $ | (1,759) | |||||||||||
Issuance of shares and pre-funded warrants, net | 5,981,238 | - | 10,806 | - | 10,806 | |||||||||||||||
Exercise of pre-funded warrants, options and | 1,573,000 | - | (*) | - | (*) | |||||||||||||||
Issuance of shares due to SEPA agreement | 224,697 | 281 | - | 281 | ||||||||||||||||
Reclassification of warrants into equity (see | - | - | 1,695 | (329) | 1,366 | |||||||||||||||
Bonus accrual reclassification to equity (see | - | - | 1,434 | - | 1,434 | |||||||||||||||
Share-based compensation | 70,964 | - | 665 | - | 665 | |||||||||||||||
Net loss and comprehensive loss | - | - | - | (10,210) | (10,210) | |||||||||||||||
Balance as of December 31, 2024 | 23,228,941 | $ | - | $ | 39,243 | $ | (36,660) | $ | 2,583 | |||||||||||
(*) less than $1. | ||||||||||||||||||||
About ALS
Amyotrophic lateral sclerosis ("ALS") is an incurable neurodegenerative disease that causes complete paralysis and death within 2-5 years from diagnosis. Every year, more than 5,000 people are diagnosed with ALS in the U.S. alone, with an annual disease burden of $1 billion. The number of people living with ALS is expected to grow by 24% by 2040 in the U.S. and EU.
About PrimeC
PrimeC, NeuroSense's lead drug candidate, is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. PrimeC is designed to synergistically target several key mechanisms of ALS that contribute to motor neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid ("RNA") regulation to potentially inhibit the progression of ALS. NeuroSense completed a Phase 2a clinical trial which met its safety and efficacy endpoints including reducing functional and respiratory deterioration and statistically significant changes in ALS-related biological markers indicating PrimeC's biological activity. PrimeC was granted Orphan Drug Designation by the U.S. Food and Drug Administration and the European Medicines Agency.
About NeuroSense
NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases.
For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels.
Forward-Looking Statements
This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics' current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and include statements regarding ongoing partnership discussions, the timing of initiation of studies, regulatory filings, meetings and regulatory decisions, market potential and expected growth in the market. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include the risk that the partnership discussions will not lead to execution of a definitive agreement, or that, if executed, will not lead to the current anticipated benefits to NeuroSense, a delay in the planned Phase 3 study for PrimeC in ALS, lower than anticipated market opportunity in Canada and elsewhere, that regulatory approvals for PrimeC will be delayed or not obtained in Canada or elsewhere; unexpected R&D costs or operating expenses, insufficient capital to complete development of PrimeC, a delay in the development of PrimeC, the timing of expected regulatory and business milestones, risks associated with meeting with the FDA and Health Canada to determine the best path forward following the results from PARADIGM clinical trial, including a delay in any such meeting; the potential for PrimeC to safely and effectively target ALS; preclinical and clinical data for PrimeC; the uncertainty regarding outcomes and the timing of current and future clinical trials; timing for reporting data; the development and commercial potential of any product candidates of Neurosense; the ability of NeuroSense to remain listed on Nasdaq; and other risks and uncertainties set forth in NeuroSense's filings with the Securities and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future. More information about the risks and uncertainties affecting NeuroSense is contained under the heading "Risk Factors" in the Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 7, 2025 and NeuroSense's subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable law.
This News is brought to you by Qube Mark, your trusted source for the latest updates and insights in marketing technology. Stay tuned for more groundbreaking innovations in the world of technology.
